+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Human Growth Hormone Market Report and Forecast 2023-2031

  • PDF Icon

    Report

  • 140 Pages
  • July 2023
  • Region: Global
  • Expert Market Research
  • ID: 5855165
The global human growth hormone market attained a value of USD 5.2 billion in 2022, driven by increasing prevalence of growth hormone deficiency, growing demand for anti-aging treatments, and advancements in HGH formulations and delivery systems. The market is expected to grow at a CAGR of 8.49% during the forecast period of 2023-2031 to attain a value of USD 10.8 billion by 2031.

Human Growth Hormone: Introduction

Human growth hormone (HGH), also known as somatotropin, is a hormone produced naturally by the pituitary gland in the brain. It plays a vital role in stimulating growth and cell reproduction in humans. HGH is involved in various physiological processes and offers several uses and benefits.

The benefits of human growth hormone include:

  • Growth and Development: HGH promotes normal growth and development in children and adolescents, ensuring proper bone growth, organ development, and overall physical maturation
  • Enhanced Muscle Function: HGH helps increase muscle mass, improve muscle strength, and enhance exercise performance. It is commonly used by athletes and bodybuilders to support muscle growth and improve athletic performance
  • Anti-Aging Effects: HGH has been associated with anti-aging effects, including improved skin elasticity, reduced wrinkles, and increased collagen production. It is believed to contribute to a more youthful appearance
  • Enhanced Healing and Recovery: Human growth hormone aids in tissue repair, wound healing, and recovery from injuries. It can help accelerate healing in certain conditions and improve recovery after surgeries or traumatic events
  • Metabolic Benefits: HGH plays a role in regulating metabolism, promoting fat breakdown, and supporting the development of lean muscle mass. It can help improve body composition, increase energy levels, and enhance metabolic functions
It is important to note that the use of human growth hormone should be under medical supervision. HGH therapy is prescribed in specific medical conditions, such as growth hormone deficiency, Turner syndrome, Prader-Willi syndrome, and certain chronic conditions. Self-administration or misuse of HGH without proper medical guidance can have adverse effects on health.

Human Growth Hormone Market Segmentations

The market can be categorised into application, distribution channel, and region.

Market Breakup by Application

  • Growth Hormone Deficiency
  • Turner Syndrome
  • Idiopathic Short Stature
  • Prader-Willi Syndrome
  • Other Applications

Market Breakup by Distribution Channel

  • Hospitals and Retail Pharmacies
  • Online Pharmacies
  • Other Distribution Channels

Market Breakup by Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

Human Growth Hormone Market Overview

The human growth hormone (HGH) market has witnessed substantial growth and is expected to continue expanding in the coming years. Several factors contribute to the positive market scenario.

One of the primary drivers of market growth is the increasing prevalence of growth hormone deficiency and related disorders. Growth hormone deficiency can occur in children and adults, leading to growth retardation, short stature, and other health complications. The growing awareness and early diagnosis of these conditions have increased the demand for HGH therapy, driving market growth.

Moreover, the rising interest in anti-aging treatments and the pursuit of a youthful appearance have contributed to the market expansion. HGH is often associated with anti-aging effects, such as improved skin elasticity, reduced wrinkles, and increased muscle tone. The desire for youthful aesthetics and the demand for cosmetic enhancements have fuelled the market demand for HGH.

Furthermore, advancements in technology and pharmaceutical formulations have enhanced the availability and administration of HGH products. The development of long-acting formulations and innovative delivery systems has improved patient convenience and compliance. These advancements have made HGH therapy more accessible and user-friendly, positively impacting the market growth.

Additionally, the growing prevalence of chronic conditions such as Turner syndrome, Prader-Willi syndrome, and growth hormone deficiency associated with renal insufficiency has expanded the market for HGH. These conditions require long-term HGH therapy to manage symptoms, improve growth, and enhance quality of life.

Key Players in the Global Human Growth Hormone Market

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the human growth hormone market are as follows:
  • AnkeBio Co. Ltd
  • Eli Lilly and Company
  • Ferring BV
  • Novo Nordisk AS
  • Ipsen SA
  • Pfizer Inc
  • Genentech Inc. (Roche)
  • Teva Pharmaceutical Industries Ltd
  • Ferring BV
  • Anhui Anke Biotechnology (Group) Co
*The publisher always strives to provide you with the latest information. The numbers in the article are only indicative and may be different from the actual report.

Table of Contents

1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Human Growth Hormone Market Overview
3.1 Global Human Growth Hormone Market Historical Value (2016-2022)
3.2 Global Human Growth Hormone Market Forecast Value (2023-2031)
4 Global Human Growth Hormone Market Dynamics
4.1 Market Drivers and Constraints
4.2 SWOT Analysis
4.3 Porter’s Five Forces Model
4.4 Key Demand Indicators
4.5 Key Price Indicators
4.6 Industry Events, Initiatives, and Trends
4.7 Value Chain Analysis
5 Global Human Growth Hormone Market Segmentation
5.1 Global Human Growth Hormone Market by Application
5.1.1 Market Overview
5.1.2 Growth Hormone Deficiency
5.1.3 Turner Syndrome
5.1.4 Idiopathic Short Stature
5.1.5 Prader-Willi Syndrome
5.1.6 Other Applications
5.2 Global Human Growth Hormone Market by Distribution Channel
5.2.1 Market Overview
5.2.2 Hospitals and Retail Pharmacies
5.2.3 Online Pharmacies
5.2.4 Other Distribution Channels
5.3 Global Human Growth Hormone Market by Region
5.3.1 Market Overview
5.3.2 North America
5.3.3 Europe
5.3.4 Asia Pacific
5.3.5 Latin America
5.3.6 Middle East and Africa
6 North America Growth Hormone Market
6.1 Market Share by Country
6.2 United States of America
6.3 Canada
7 Europe Human Growth Hormone Market
7.1 Market Share by Country
7.2 United Kingdom
7.3 Germany
7.4 France
7.5 Italy
7.6 Others
8 Asia Pacific Human Growth Hormone Market
8.1 Market Share by Country
8.2 China
8.3 Japan
8.4 India
8.5 ASEAN
8.6 Australia
8.7 Others
9 Latin America Human Growth Hormone Market
9.1 Market Share by Country
9.2 Brazil
9.3 Argentina
9.4 Mexico
9.5 Others
10 Middle East and Africa Human Growth Hormone Market
10.1 Market Share by Country
10.2 Saudi Arabia
10.3 United Arab Emirates
10.4 Nigeria
10.5 South Africa
10.6 Others
11 Regulatory Framework
11.1 Regulatory Overview
11.1.1 US FDA
11.1.2 EU EMA
11.1.3 INDIA CDSCO
11.1.4 JAPAN PMDA
11.1.5 Others
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Clinical Trials Analysis
14.1 Analysis by Trial Registration Year
14.2 Analysis by Trial Status
14.3 Analysis by Trial Phase
14.4 Analysis by Therapeutic Area
14.5 Analysis by Geography
15 Funding and Investment Analysis
15.1 Analysis by Funding Instances
15.2 Analysis by Type of Funding
15.3 Analysis by Funding Amount
15.4 Analysis by Leading Players
15.5 Analysis by Leading Investors
15.6 Analysis by Geography
16 Partnership and Collaborations Analysis
16.1 Analysis by Partnership Instances
16.2 Analysis by Type of Partnership
16.3 Analysis by Leading Players
16.4 Analysis by Geography
17 Supplier Landscape
17.1 AnkeBio Co. Ltd
17.1.1 Financial Analysis
17.1.2 Product Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisitions
17.1.5 Certifications
17.2 Eli Lilly and Company
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisitions
17.2.5 Certifications
17.3 Ferring BV
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisitions
17.3.5 Certifications
17.4 Novo Nordisk AS
17.4.1 Financial Analysis
17.4.2 Product Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisitions
17.4.5 Certifications
17.5 Ipsen SA
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisitions
17.5.5 Certifications
17.6 Pfizer Inc.
17.6.1 Financial Analysis
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisitions
17.6.5 Certifications
17.7 Genentech Inc. (Roche)
17.7.1 Financial Analysis
17.7.2 Product Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Mergers and Acquisitions
17.7.5 Certifications
17.8 Teva Pharmaceutical Industries Ltd.
17.8.1 Financial Analysis
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisitions
17.8.5 Certifications
17.9 Ferring BV
17.9.1 Financial Analysis
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisitions
17.9.5 Certifications
17.10 Anhui Anke Biotechnology (Group) Co.
17.10.1 Financial Analysis
17.10.2 Product Portfolio
17.10.3 Demographic Reach and Achievements
17.10.4 Mergers and Acquisitions
17.10.5 Certifications
18 Key Opinion Leaders (KOL) Insights (Additional Insight)
19 Company Competitiveness Analysis (Additional Insight)
19.1 Very Small Companies
19.2 Small Companies
19.3 Mid-Sized Companies
19.4 Large Companies
19.5 Very Large Companies
20 Payment Methods (Additional Insight)
20.1 Government Funded
20.2 Private Insurance
20.3 Out-of-Pocket
  • *Additional insights provided are customisable as per client requirements.

Companies Mentioned

  • AnkeBio Co. Ltd
  • Eli Lilly and Company
  • Ferring BV
  • Novo Nordisk AS
  • Ipsen SA
  • Pfizer Inc.
  • Genentech Inc. (Roche)
  • Teva Pharmaceutical Industries Ltd.
  • Ferring BV
  • Anhui Anke Biotechnology (Group) Co.

Methodology

Loading
LOADING...

Table Information